Spots Global Cancer Trial Database for Bisantrene for Relapsed /Refractory AML
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bisantrene for Relapsed /Refractory AML
Official Title: Bisantrene for Relapsed /Refractory Acute Myelogenous Leukemia (AML)
Study ID: NCT03820908
Interventions
Study Description
Brief Summary: Induction of response in patients with AML that are either primary resistant (failed induction and or salvage therapy) or relapsed including post allogeneic stem cell transplantation and failed salvage therapy or cannot receive additional anthracycline .
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chaim Sheba Medical Center, Ramat Gan, , Israel
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
